ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)

Market Cap	1.91B -31.6%
Revenue (ttm)	797.57M -6.1%
Net Income	22.33M +9.7%
EPS	0.09 +8.3%
Shares Out	257.21M
PE Ratio	82.10
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,947,640
Open	7.65
Previous Close	7.60
Day's Range	7.37 - 7.65
52-Week Range	6.93 - 15.20
Beta	0.58
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 28, 2026

About SHE:300254

ShanXi C&Y Pharmaceutical Group Co.,LTD. engages in the research, development, production, and sale of medicine and health food products. It provides anti-infective drugs, anti-allergic drugs, smoking cessation drugs, pediatric drugs, respiratory system drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, nephropathy drugs, anti-depressants, medicines, pharmaceutical raw materials, and intermediates, commerce, etc. The company’s product portfolio includes Fosfomycin tromethamine powder, ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2005
• Employees: 1,162
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300254

Financial Performance

In 2025, SHE:300254's revenue was 870.79 million, an increase of 2.86% compared to the previous year's 846.61 million. Earnings were 24.85 million, a decrease of -41.10%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 13, 2026

Data Sources Report a data error